Sign up

Bellevue Group AG

$4.8B assets · 148 holdings · Q2 2026 · Filed 14 AUG 2026

About Bellevue Group AG’s 13F portfolio

Bellevue Group AG is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Bellevue Group AG reported $4.8B across 148 US-listed positions (). Its largest position is AMGEN INC (AMGN) at 6.5% of the reported book, and its ten biggest holdings make up 43% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$4.8B
Assets (13F)
#844
of 8,839 by size
148
Holdings
43%
Top-10 weight
58
Buys
90
Sells
Top holdings · Q2 2026
148 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: AMGN
AMGEN INC
$443.89
−3.07%
6.5%
852K$308.4M
2
NASDAQ: VRTX
VERTEX PHARMACEUTICALS INC
$536.45
+0.42%
6.0%
579K$287.4M
3
NASDAQ: ARGX
ARGENX SE
$941.25
−0.66%
5.9%
301K$279.3M
4
NASDAQ: GILD
GILEAD SCIENCES INC
$168.98
−0.75%
5.7%
2.2M$272.7M
5
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.82
−1.76%
4.1%
1.0M$196.3M
6
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
$95.74
−0.60%
3.3%
1.7M$157.7M
7
NASDAQ: INSM
INSMED INC
$119.80
−1.69%
3.1%
1.4M$148.6M
8
NASDAQ: SRRK
SCHOLAR ROCK HLDG CORP
$48.00
+6.48%
2.8%
2.4M$134.7M
9
NASDAQ: NUVL
NUVALENT INC
$123.96
0.00%
2.7%
1.1M$130.1M
10
NASDAQ: VRDN
VIRIDIAN THERAPEUTICS INC
$30.12
+0.20%
2.6%
6.7M$123.7M
11
NASDAQ: RLAY
RELAY THERAPEUTICS INC
$16.51
+0.24%
2.4%
6.2M$115.7M
12
NASDAQ: PCVX
VAXCYTE INC
$58.52
−1.48%
2.4%
2.0M$114.6M
13
NASDAQ: UTHR
UNITED THERAPEUTICS CORP DEL
$577.34
−1.16%
2.1%
189K$102.1M
14
NASDAQ: ISRG
INTUITIVE SURGICAL INC
$420.95
−2.23%
2.1%
255K$101.3M
15
NASDAQ: REGN
REGENERON PHARMACEUTICALS
$945.53
−1.28%
2.1%
157K$98.1M
16
NASDAQ: CRNX
CRINETICS PHARMACEUTICALS IN
$84.95
0.00%
2.1%
2.6M$98.0M
17
NASDAQ: BBIO
BRIDGEBIO PHARMA INC
$78.01
+1.58%
1.9%
1.2M$88.6M
18
NASDAQ: IMCR
IMMUNOCORE HLDGS PLC
$27.51
−1.08%
1.9%
2.8M$88.5M
19
NYSE: ABT
ABBOTT LABORATORIES
$104.48
−0.22%
1.8%
947K$85.9M
20
NYSE: SYK
STRYKER CORPORATION
$318.15
+0.19%
1.8%
268K$84.5M
21
NYSE: MDT
MEDTRONIC PLC
$100.72
−1.56%
1.6%
994K$77.8M
22
NASDAQ: IONS
IONIS PHARMACEUTICALS INC
$27.39
+1.59%
1.6%
972K$77.1M
23
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
$44.89
−4.18%
1.6%
1.5M$75.6M
24
NASDAQ: VERA
VERA THERAPEUTICS INC
$25.58
−2.37%
1.5%
1.7M$73.4M
25
NASDAQ: JBIO
JADE BIOSCIENCES INC
$15.49
+0.58%
1.4%
3.1M$67.9M

Showing 1–25 of 148 positions on this page reported in this 13F.

Sector allocation
  • Healthcare97%
  • Technology0.0%
  • Communication Services0.0%
  • Consumer Cyclical0.0%
Recent activity · vs 2026-03-31
Bought58
  • AddedAMGNAMGEN INC+188%$308.4M
  • AddedGILDGILEAD SCIENCES INC+84.5%$272.7M
  • AddedORKAORUKA THERAPEUTICS INC+227%$157.7M
  • AddedINSMINSMED INC+13787%$148.6M
  • AddedVRDNVIRIDIAN THERAPEUTICS INC+0.1%$123.7M
  • AddedPCVXVAXCYTE INC+65.6%$114.6M
  • AddedUTHRUNITED THERAPEUTICS CORP DEL+8976%$102.1M
  • AddedBBIOBRIDGEBIO PHARMA INC+4587%$88.6M
  • AddedSYKSTRYKER CORPORATION+23.6%$84.5M
  • AddedMDTMEDTRONIC PLC+3.9%$77.8M
Sold90
  • ReducedVRTXVERTEX PHARMACEUTICALS INC−15.1%$287.4M
  • ReducedARGXARGENX SE−3.8%$279.3M
  • ReducedRVMDREVOLUTION MEDICINES INC−32.1%$196.3M
  • ReducedSRRKSCHOLAR ROCK HLDG CORP−31.7%$134.7M
  • ReducedRLAYRELAY THERAPEUTICS INC−20.6%$115.7M
  • ReducedISRGINTUITIVE SURGICAL INC−11.1%$101.3M
  • ReducedREGNREGENERON PHARMACEUTICALS−43.6%$98.1M
  • ReducedCRNXCRINETICS PHARMACEUTICALS IN−20.1%$98.0M
  • ReducedIMCRIMMUNOCORE HLDGS PLC−0.3%$88.5M
  • ReducedABTABBOTT LABORATORIES−17.8%$85.9M
5%+ Beneficial Ownership Stakes · 2 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
JBIO
Jade Biosciences, Inc.
13G6.8% · 2 classes4.3MFiled 16 NOV 2026
2
CLDX
Celldex Therapeutics, Inc.
13G5.4%3.6MFiled 14 NOV 2025

Showing all 2 disclosed stakes.

Reading Bellevue Group AG’s 13F portfolio

Bellevue Group AG’s $4.8B 13F book is spread across 148 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 43%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are AMGN, VRTX, ARGX, GILD and RVMD, led by AMGEN INC (AMGN) at 6.5% of the portfolio. The heaviest sector exposure is Healthcare (97%), then Technology (0%).

What Bellevue Group AG changed last quarter

Between 2026-03-31 and Q2 2026, Bellevue Group AG was a net seller: it opened 17 new positions and added to 41 more, while trimming 66 and closing 24 outright. Against a 148-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was AMGEN INC (AMGN), and its biggest reduction was VERTEX PHARMACEUTICALS INC (VRTX).

What a 13F does and doesn’t reveal

A 13F captures only Bellevue Group AG’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Bellevue Group AG is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Bellevue Group AG's profile on this page is built directly from those filings.

How current is the 13F data on Bellevue Group AG's page?

It reflects Bellevue Group AG's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Bellevue Group AG files its next quarterly report, this page refreshes automatically.

Can I see Bellevue Group AG's complete list of holdings?

This page highlights Bellevue Group AG's largest positions rather than all 148 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Bellevue Group AG's filings.

Does a 13F show everything Bellevue Group AG owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Bellevue Group AG's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Bellevue Group AG made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.